Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA) | MicrobiomeTrials
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2026-04-07Est. Completion: 2027-05-30
Enrollment target: 5 participants
Locations
Beijing GoBroad Boren Hospital, Beijing, Beijing Municipality, China